{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:13:59Z","timestamp":1790687639773,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jhep.2023.03.014","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T15:25:31Z","timestamp":1680103531000},"page":"829-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-0733","authenticated-orcid":false,"given":"Raluca","family":"Pais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8040","authenticated-orcid":false,"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-8618","authenticated-orcid":false,"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadi","family":"Lalazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-7817","authenticated-orcid":false,"given":"Sharat","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-8297","authenticated-orcid":false,"given":"Julie","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3224","authenticated-orcid":false,"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.03.014_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/dom.14322","article-title":"Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review","volume":"23","author":"Cariou","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.03.014_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.gastro.2017.07.024","article-title":"Baseline parameters in clinical trials for nonalcoholic steatohepatitis: recommendations from the liver Forum","volume":"153","author":"Patel","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.29607","article-title":"Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science","volume":"67","author":"Siddiqui","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver Forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/j.gastro.2019.08.048","article-title":"Factors to consider in development of drugs for pediatric nonalcoholic fatty liver disease","volume":"157","author":"Vos","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2020.04.039","article-title":"Attribution of nonalcoholic steatohepatitis as an etiology of cirrhosis for clinical trials eligibility: recommendations from the multi-stakeholder liver Forum","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2023.03.014_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2020.04.030","article-title":"Standardisation of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the Liver Forum","volume":"73","author":"Glass","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib9","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes care"},{"key":"10.1016\/j.jhep.2023.03.014_bib10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A\u00a0systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/jhep.2002.30318","article-title":"Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib13","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.bjc.6602819","article-title":"Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria","volume":"93","author":"Rapp","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2023.03.014_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00125-006-0207-6","article-title":"Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria","volume":"49","author":"Rapp","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.03.014_bib15","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jhep.2016.01.014","article-title":"Type 2 diabetes and risk of hospital admission or death for chronic liver diseases","volume":"64","author":"Wild","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1053\/j.gastro.2013.08.036","article-title":"Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis","volume":"145","author":"Siddiqui","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.23094","article-title":"Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis","volume":"50","author":"Fujita","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/liv.13076","article-title":"Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease","volume":"36","author":"Jiang","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.03.014_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2014.05.023","article-title":"Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia","volume":"61","author":"Di Filippo","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib21","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.01.009","article-title":"Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension","volume":"60","author":"Sung","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057183","article-title":"Non-alcoholic fatty liver disease is associated with an increased incidence of\u00a0atrial fibrillation in patients with type 2 diabetes","volume":"8","author":"Targher","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.03.014_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2016.02.023","article-title":"Fatty liver is an independent predictor of early carotid atherosclerosis","volume":"65","author":"Pais","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.28253","article-title":"Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study","volume":"63","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney\u00a0disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"Plos Med"},{"key":"10.1016\/j.jhep.2023.03.014_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jhep.2017.09.020","article-title":"Advanced\u00a0liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes","volume":"68","author":"Yeung","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2011.04.022","article-title":"Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese","volume":"56","author":"Aron-Wisnewsky","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jhep.2023.03.014_bib29","first-page":"1521","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Lin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/gutjnl-2015-310069","article-title":"Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome","volume":"64","author":"Cauchy","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.03.014_bib31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.03.014_bib32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.03.014_bib33","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.03.014_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/13543784.2021.1951701","article-title":"Anti-diabetic drugs and NASH: from current options to promising perspectives","volume":"30","author":"Smati","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2023.03.014_bib35","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.014_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jhep.2023.03.014_bib39","series-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment guidance for industry","article-title":"U.S. Department of health and human services Food and drug administration center for drug evaluation and research (CDER)","year":"2018"},{"key":"10.1016\/j.jhep.2023.03.014_bib40","series-title":"Draft reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","year":"2018"},{"key":"10.1016\/j.jhep.2023.03.014_bib41","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1038\/s41598-018-27377-2","article-title":"Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study","volume":"8","author":"Zhou","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.03.014_bib42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"24","key":"10.1016\/j.jhep.2023.03.014_bib43","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jhep.2023.03.014_bib44","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib45","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jhep.2023.03.014_bib46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.014_bib47","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2023.03.014_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11938-018-0180-4","article-title":"The use of statins in patients with chronic liver disease and cirrhosis","volume":"16","author":"Moctezuma-Velazquez","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.jhep.2023.03.014_bib49","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib50","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib52","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2017.10.018","article-title":"Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study","volume":"68","author":"Kim","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib53","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/hepr.12887","article-title":"Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis","volume":"47","author":"Nakade","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2023.03.014_bib54","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamacardio.2020.5341","article-title":"Genetic inhibition of PCSK9 and liver function","volume":"6","author":"Rimbert","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jhep.2023.03.014_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/JCI128650","article-title":"The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and\u00a0GRP94 and protects against liver injury","volume":"131","author":"Lebeau","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2023.03.014_bib57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jhep.2013.02.024","article-title":"Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome","volume":"59","author":"Van Rooyen","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib58","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015","volume":"317","author":"Forouzanfar","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.03.014_bib59","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1001\/jama.287.20.2677","article-title":"Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT)","volume":"287","author":"Domanski","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.03.014_bib60","first-page":"e426","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2023.03.014_bib61","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jhep.2023.03.014_bib62","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.014_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"Brunstrom","year":"2018","journal-title":"JAMA Int Med"},{"key":"10.1016\/j.jhep.2023.03.014_bib64","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.24558","article-title":"Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial","volume":"54","author":"Torres","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163069","article-title":"Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease","volume":"11","author":"Pelusi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.03.014_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175717","article-title":"A\u00a0randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis","volume":"12","author":"McPherson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.03.014_bib67","article-title":"Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease","author":"Zhang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-230X-13-3","article-title":"Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population","volume":"13","author":"Ma","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2023.03.014_bib69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11695-017-2829-9","article-title":"Type 2 diabetes mellitus and simple glucose metabolism parameters may reliably predict nonalcoholic fatty liver disease features","volume":"28","author":"Cazzo","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.jhep.2023.03.014_bib70","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/diacare.23.10.1478","article-title":"Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans affairs cooperative study on glycemic control and complications in type 2 diabetes feasibility trial investigators","volume":"23","author":"Levin","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.03.014_bib71","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2023.03.014_bib72","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc09-0148","article-title":"Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis","volume":"33","author":"Hamaguchi","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.03.014_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.03.014_bib74","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.2337\/dc19-S006","article-title":"Glycemic targets: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.03.014_bib75","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year\u00a0results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib76","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib77","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.014_bib78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.014_bib79","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.03.014_bib80","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.03.014_bib81","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahren","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2023.03.014_bib82","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib83","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A\u00a0meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib84","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib85","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American heart association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2023.03.014_bib86","first-page":"1407","article-title":"Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects","volume":"80","author":"Rasmussen","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.03.014_bib87","doi-asserted-by":"crossref","first-page":"e3624","DOI":"10.1210\/clinem\/dgac405","article-title":"The GH\/IGF-1 Axis is associated with intrahepatic lipid content and hepatocellular damage in overweight\/obesity","volume":"107","author":"Dichtel","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2023.03.014_bib88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1478-3231.2011.02637.x","article-title":"Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients","volume":"32","author":"Koehler","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.03.014_bib89","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s12072-018-9893-7","article-title":"Metabolic effects of reduced growth hormone action in fatty liver disease","volume":"12","author":"Rufinatscha","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.03.014_bib90","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrendo.2013.122","article-title":"Testosterone and insulin resistance in the\u00a0metabolic syndrome and T2DM in men","volume":"9","author":"Rao","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2023.03.014_bib91","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1210\/en.2015-1713","article-title":"Androgen deficiency exacerbates high-fat diet-induced metabolic alterations in male mice","volume":"157","author":"Dubois","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.jhep.2023.03.014_bib92","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cgh.2019.11.053","article-title":"Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men","volume":"19","author":"Sarkar","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib93","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jim-2015-000019","article-title":"Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes","volume":"64","author":"Bril","year":"2016","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.jhep.2023.03.014_bib94","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.cgh.2018.11.024","article-title":"Low-normal thyroid function is associated with advanced fibrosis among\u00a0adults in the United States","volume":"17","author":"Kim","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12902-015-0030-5","article-title":"Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years","volume":"15","author":"Ludwig","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jhep.2023.03.014_bib96","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","article-title":"Non-alcoholic fatty liver disease across the spectrum of hypothyroidism","volume":"57","author":"Chung","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib97","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.14309\/ajg.0000000000000654","article-title":"Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality","volume":"115","author":"Kim","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.03.014_bib98","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib99","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib100","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib101","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib102","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.03.014_bib103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0895-4356(98)00138-3","article-title":"Stratified randomization for clinical trials","volume":"52","author":"Kernan","year":"1999","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhep.2023.03.014_bib104","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.279.3.222","article-title":"Run-in periods in randomized trials: implications for the application of results in clinical practice","volume":"279","author":"Pablos-Mendez","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2023.03.014_bib105","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cardfail.2017.07.401","article-title":"Why has a run-in period been a design element in most landmark clinical trials? Analysis of the critical role of run-in periods in drug development","volume":"23","author":"Packer","year":"2017","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jhep.2023.03.014_bib106","series-title":"Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus","year":"2012"},{"key":"10.1016\/j.jhep.2023.03.014_bib107","series-title":"Guideline on clinical investigation of medicinal products in the treatment of hypertension","year":"2016"},{"key":"10.1016\/j.jhep.2023.03.014_bib108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/obr.12111","article-title":"Association of run-in periods with weight loss in obesity randomized controlled trials","volume":"15","author":"Affuso","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.jhep.2023.03.014_bib109","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib110","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib111","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1740774519844259","article-title":"A\u00a0note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis","volume":"16","author":"Mehrotra","year":"2019","journal-title":"Clin Trials"},{"key":"10.1016\/j.jhep.2023.03.014_bib112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib113","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2023.03.014_bib114","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.03.014_bib115","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00125-012-2524-2","article-title":"Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience","volume":"55","author":"Bonds","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2023.03.014_bib116","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2023.03.014_bib117","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrgastro.2018.8","article-title":"Women and alcoholic liver disease - warning of a silent danger","volume":"15","author":"Szabo","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib118","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/00365520802555991","article-title":"Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease","volume":"44","author":"Ekstedt","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.03.014_bib119","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/hep.31539","article-title":"Measuring the alcohol in alcohol-associated liver disease: choices and challenges for clinical research","volume":"73","author":"Mellinger","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.03.014_bib121","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/acer.13558","article-title":"Applications and challenges for the use of phosphatidylethanol testing in liver disease patients (mini review)","volume":"42","author":"Nguyen","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhep.2023.03.014_bib122","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/tri.12949","article-title":"Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study","volume":"30","author":"Andresen-Streichert","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2023.03.014_bib123","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease","volume":"77","author":"Staufer","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.03.014_bib124","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/1556-4029.13874","article-title":"The PEth blood test in the security environment: what it is; why it is important; and interpretative guidelines","volume":"63","author":"Ulwelling","year":"2018","journal-title":"J\u00a0Forensic Sci"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823001897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823001897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T18:46:05Z","timestamp":1718736365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823001897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0168827823001897"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.03.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}